Literature DB >> 33655678

European clinical practice recommendations on opioids for chronic noncancer pain - Part 2: Special situations.

Nevenka Krčevski Škvarč1, Bart Morlion2, Kevin E Vowles3, Kirsty Bannister4, Eric Buchsner5, Roberto Casale6, Jean-François Chenot7, Gillian Chumbley8, Asbjørn Mohr Drewes9, Geert Dom10, Liisa Jutila11, Tony O'Brien12, Esther Pogatzki-Zahn13, Martin Rakusa14, Carmen Suarez-Serrano15, Thomas Tölle16, Winfried Häuser17,18.   

Abstract

BACKGROUND: Opioid use for chronic non-cancer pain (CNCP) is under debate. In the absence of pan-European guidance on this issue, a position paper was commissioned by the European Pain Federation (EFIC).
METHODS: The clinical practice recommendations were developed by eight scientific societies and one patient self-help organization under the coordination of EFIC. A systematic literature search in MEDLINE (up until January 2020) was performed. Two categories of guidance are given: Evidence-based recommendations (supported by evidence from systematic reviews of randomized controlled trials or of observational studies) and Good Clinical Practice (GCP) statements (supported either by indirect evidence or by case-series, case-control studies and clinical experience). The GRADE system was applied to move from evidence to recommendations. The recommendations and GCP statements were developed by a multiprofessional task force (including nursing, service users, physicians, physiotherapy and psychology) and formal multistep procedures to reach a set of consensus recommendations. The clinical practice recommendations were reviewed by five external reviewers from North America and Europe and were also posted for public comment.
RESULTS: The European Clinical Practice Recommendations give guidance for combination with other medications, the management of frequent (e.g. nausea, constipation) and rare (e.g. hyperalgesia) side effects, for special clinical populations (e.g. children and adolescents, pregnancy) and for special situations (e.g. liver cirrhosis).
CONCLUSION: If a trial with opioids for chronic noncancer pain is conducted, detailed knowledge and experience are needed to adapt the opioid treatment to a special patient group and/or clinical situation and to manage side effects effectively. SIGNIFICANCE: If a trial with opioids for chronic noncancer pain is conducted, detailed knowledge and experience are needed to adapt the opioid treatment to a special patient group and/or clinical situation and to manage side effects effectively. A collaboration of medical specialties and of all health care professionals is needed for some special populations and clinical situations.
© 2021 The Authors. European Journal of Pain published by John Wiley & Sons Ltd on behalf of European Pain Federation - EFIC ®.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33655678     DOI: 10.1002/ejp.1744

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  3 in total

1.  European* clinical practice recommendations on opioids for chronic noncancer pain - Part 1: Role of opioids in the management of chronic noncancer pain.

Authors:  Winfried Häuser; Bart Morlion; Kevin E Vowles; Kirsty Bannister; Eric Buchser; Roberto Casale; Jean-François Chenot; Gillian Chumbley; Asbjørn Mohr Drewes; Geert Dom; Liisa Jutila; Tony O'Brien; Esther Pogatzki-Zahn; Martin Rakusa; Carmen Suarez-Serrano; Thomas Tölle; Nevenka Krčevski Škvarč
Journal:  Eur J Pain       Date:  2021-03-02       Impact factor: 3.931

Review 2.  Bioequivalence, Drugs with Narrow Therapeutic Index and The Phenomenon of Biocreep: A Critical Analysis of the System for Generic Substitution.

Authors:  Lucia Gozzo; Filippo Caraci; Filippo Drago
Journal:  Healthcare (Basel)       Date:  2022-07-26

3.  System-level policies on appropriate opioid use, a multi-stakeholder consensus.

Authors:  Patrice Forget; Champika Patullo; Duncan Hill; Atul Ambekar; Alex Baldacchino; Juan Cata; Sean Chetty; Felicia J Cox; Hans D de Boer; Kieran Dinwoodie; Geert Dom; Christopher Eccleston; Brona Fullen; Liisa Jutila; Roger D Knaggs; Patricia Lavand'homme; Nicholas Levy; Dileep N Lobo; Esther Pogatzki-Zahn; Norbert Scherbaum; Blair H Smith; Joop van Griensven; Steve Gilbert
Journal:  BMC Health Serv Res       Date:  2022-03-12       Impact factor: 2.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.